Business Description
TransCode Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US89357L5012
Total Employee Number:
12Description
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 96.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 79.11 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.78 | |||||
9-Day RSI | 65.48 | |||||
14-Day RSI | 57.64 | |||||
3-1 Month Momentum % | -40.3 | |||||
6-1 Month Momentum % | -24.74 | |||||
12-1 Month Momentum % | -34.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.11 | |||||
Quick Ratio | 3.11 | |||||
Cash Ratio | 2.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -64.21 | |||||
ROA % | -58.28 | |||||
ROIC % | -57.94 | |||||
3-Year ROIIC % | -0.26 | |||||
ROC (Joel Greenblatt) % | -24905.12 | |||||
ROCE % | -60.39 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.57 | |||||
EV-to-Forward-Revenue | 1.25 | |||||
EV-to-FCF | -0.01 | |||||
| Price-to-Net-Cash | 29.57 | |||||
FCF Yield % | -362.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNAZ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TransCode Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -50.33 | ||
| Beta | 3.6166 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.96 | ||
| Volatility % | 83.87 | ||
| 14-Day RSI | 57.64 | ||
| 14-Day ATR ($) | 0.734049 | ||
| 20-Day SMA ($) | 5.25725 | ||
| 12-1 Month Momentum % | -34.1 | ||
| 52-Week Range ($) | 3.82 - 20.99 | ||
| Shares Outstanding (Mil) | 0.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TransCode Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TransCode Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 135 days | ||
| General meeting for 2027 | 2026-08-28 09:30 | In 59 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 44 days | ||
| TransCode Therapeutics to Host R&D Webcast | 2026-06-18 10:00 | 5.35 (+0.93%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 6.79 (-4.39%) | ||
| Annual report for 2025 | 2026-04-15 | 8.90 (+2.42%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 8.42 (-6.34%) | ||
| General meeting for 2025 | 2025-08-29 09:30 | 9.88 (-1.89%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 11.59 (-1.36%) | ||
| 0.0357143:1 Stock Split | 2025-05-15 | 9.71 (-0.14%) |
Show
Entries
TransCode Therapeutics Inc Frequently Asked Questions
What is TransCode Therapeutics Inc(RNAZ)'s stock price today?
The current price of RNAZ is $6.21. The 52 week high of RNAZ is $20.99 and 52 week low is $3.82.
When is next earnings date of TransCode Therapeutics Inc(RNAZ)?
The next earnings date of TransCode Therapeutics Inc(RNAZ) is 2026-08-14 Est..
Does TransCode Therapeutics Inc(RNAZ) pay dividends? If so, how much?
TransCode Therapeutics Inc(RNAZ) does not pay dividend.
Guru Commentaries on NAS:RNAZ
No articles.
Press Release
Articles on TransCode Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers